The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Relmada Therapeutics, Inc(NASDAQ:RLMD)


Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing drugs to treat central nervous system (CNS) diseases and other disorders in the United States. Its lead product candidate, d-Methadone, an oral agent, which is in Phase II clinical trial for the treatment of de...
Website: http://www.relmada.com
Founded: 2004
Full Time Employees: 6
CEO: Sergio Traversa
Sector: Healthcare
Industry: Drug Manufacturers-Specialty & Generic
Relmada Therapeutics Op Cashflow Per Share ttm
Relmada Therapeutics Free Cashflow Per Share ttm
Relmada Therapeutics Cash Per Share ttm
Relmada Therapeutics (GAAP) P/E ratio ttm
Relmada Therapeutics P/B ratio ttm
No extra charts and metrics for this ticker.